Avecho Biotechnology Dividends and Buybacks

Dividend criteria checks 0/6

Avecho Biotechnology does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-95.6%

Buyback Yield

Total Shareholder Yield	-95.6%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if AVE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVE's dividend payments have been increasing.

Dividend Yield vs Market

Avecho Biotechnology Dividend Yield vs Market

How does AVE dividend yield compare to the market?
Segment	Dividend Yield
Company (AVE)	n/a
Market Bottom 25% (AU)	2.6%
Market Top 25% (AU)	6.0%
Industry Average (Pharmaceuticals)	2.4%
Analyst forecast (AVE) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate AVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate AVE's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AVE has not reported any payouts.

Avecho Biotechnology Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

First half 2024 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2023)

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

New major risk - Shareholder dilution

Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in FY 2021)

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Athenex Submits Avecho's Phytonadione to FDA Pre-IND

Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia

Less than half of directors are independent

Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk

First half 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2021)

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Less than half of directors are independent

Avecho Biotechnology Limited Announces Positive Results for Its Phase IIa Study

Avecho Biotechnology Limited Announces Dosing Commencement for CBD Topical Osteoarthritis Study in collaboration with the Lambert Initiative

Full year 2021 earnings: Revenues miss analyst expectations

Avecho Biotechnology Limited Releases Results for Its Australian Phase I PK Study Characterizing the Absorption Profile of Cannabidiol from Avecho's Proprietary CBD Soft-Gel Product

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Avecho Commences Enrolment for Phase I Human Clinical Trial Measuring CBD Absorption

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Non-Independent Non-Executive Director David Segal has left the company

Avecho Biotechnology Limited Completes Pharmaceutical CBD Soft-Gel Product

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

Avecho Biotechnology Begins Human Trial on CBD Product

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Avecho Biotechnology Limited Provides TPM Cannabinoid Development Program Update

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies